Related Experiment Video
Updated: Jun 3, 2026
10:25
Pan-myeloid Differentiation of Human Cord Blood Derived CD34+ Hematopoietic Stem and Progenitor Cells
Published on: August 9, 2019
MARCH-I expression in cord blood CD34+KDR+ cells
Gioacchin Iannolo1, Maria Rita Sciuto, Cristina La Rosa
1Department Experimental Oncology, Mediterranean Institute of Oncology, Viagrande, Catania, Italy. iannolo@yahoo.com
Clinical Biochemistry
|March 10, 2011
Summary
Researchers identified a rare stem cell population, CD34+KDR+ cells, crucial for hematopoietic system regeneration. They discovered the E3 ligase MARCH-I gene, potentially key to stem cell immune properties and hematological disease treatments.
Area of Science:
- Hematology
- Stem Cell Biology
- Molecular Biology
Background:
- Hematopoietic stem cell transplantation is a vital treatment for hematological malignancies.
- Understanding stem cell repopulation mechanisms is key to advancing hematological disease therapies.
- CD34+KDR+ cells represent a rare stem cell subset with hematopoietic and endothelial potential.
Purpose of the Study:
- To investigate the unique characteristics of CD34+KDR+ cells.
- To identify genes differentially expressed in CD34+KDR+ cells compared to CD34+KDR- cells.
- To explore the role of identified genes in stem cell function.
Main Methods:
- Utilized subtraction library approach to compare gene expression between CD34+KDR+ and CD34+KDR- cells.
- Focused on identifying differentially expressed sequences.
- Characterized identified open reading frames, including E3 ligase MARCH-I.
Main Results:
- Identified several sequences with higher expression in CD34+KDR+ cells.
- Discovered an open reading frame corresponding to the E3 ligase MARCH-I.
- MARCH-I belongs to a family involved in immune response modulation via proteasomal degradation.
Conclusions:
- MARCH-I expression in stem cells may contribute to their intrinsic immune properties.
- Further research into MARCH-I function could offer new therapeutic strategies for hematological diseases.
- CD34+KDR+ cells are a promising target for understanding stem cell biology and regenerative medicine.
